Sandra Fuentes1, Megan Hahn1, Katarina Chilcote1, Roy F Chemaly2, Dimpy P Shah3, Xunyan Ye4, Vasanthi Avadhanula4, Pedro A Piedra4,5, Hana Golding1, Surender Khurana1. 1. Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD, USA. 2. The University of Texas MD Anderson Cancer Center, Houston, TX. 3. The University of Texas Health Science Center at San Antonio, TX. 4. Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, United States. 5. Department of Pediatrics, Baylor College of Medicine, Houston, TX, United States.
Abstract
BACKGROUND: Respiratory syncytial virus (RSV) infection causes significant morbidity in hematopoietic cell transplants (HCT) patients. However, antibody response that correlate with recovery from RSV disease are not fully understood. METHODS: In this study, antibody repertoire in paired serum and nasal wash samples from acutely RSV-A infected HCT patients who recovered early (<14 days RSV shedding) were compared with late-recovered patients (>14 days shedding) using gene fragment phage display libraries (GFPDL) and surface plasmon resonance (SPR). RESULTS: Anti-F serum response were similar between these two groups for antibody repertoires, neutralization titers, anti-F binding antibodies (pre-fusion and post-fusion proteins), antibody avidity and binding to specific antigenic sites. In contrast, nasal washes from early-recovered individuals demonstrated higher binding to F peptide containing p27. While the serum RSV-G antibody repertoires in the two groups were similar, the strongest difference between early-recovered and late-recovered patients was observed in the titers of nasal wash antibodies, especially binding to the central conserved domain (CCD). Most importantly, a significantly higher antibody affinity to RSV-G was observed in nasal washes from early-recovered individuals compared with late-recovered HCT patients. CONCLUSIONS: These findings highlight the importance of mucosal antibodies in resolution of RSV-A infection in the upper respiratory tract. Published by Oxford University Press for the Infectious Diseases Society of America 2019.
BACKGROUND:Respiratory syncytial virus (RSV) infection causes significant morbidity in hematopoietic cell transplants (HCT) patients. However, antibody response that correlate with recovery from RSV disease are not fully understood. METHODS: In this study, antibody repertoire in paired serum and nasal wash samples from acutely RSV-A infected HCT patients who recovered early (<14 days RSV shedding) were compared with late-recovered patients (>14 days shedding) using gene fragment phage display libraries (GFPDL) and surface plasmon resonance (SPR). RESULTS: Anti-F serum response were similar between these two groups for antibody repertoires, neutralization titers, anti-F binding antibodies (pre-fusion and post-fusion proteins), antibody avidity and binding to specific antigenic sites. In contrast, nasal washes from early-recovered individuals demonstrated higher binding to F peptide containing p27. While the serum RSV-G antibody repertoires in the two groups were similar, the strongest difference between early-recovered and late-recovered patients was observed in the titers of nasal wash antibodies, especially binding to the central conserved domain (CCD). Most importantly, a significantly higher antibody affinity to RSV-G was observed in nasal washes from early-recovered individuals compared with late-recovered HCT patients. CONCLUSIONS: These findings highlight the importance of mucosal antibodies in resolution of RSV-A infection in the upper respiratory tract. Published by Oxford University Press for the Infectious Diseases Society of America 2019.
Authors: Brittani N Blunck; Letisha Aideyan; Xunyan Ye; Vasanthi Avadhanula; Laura Ferlic-Stark; Lynn Zechiedrich; Brian E Gilbert; Pedro A Piedra Journal: Vaccine Date: 2021-12-10 Impact factor: 3.641
Authors: Xunyan Ye; Wanderson Cabral de Rezende; Obinna Patrick Iwuchukwu; Vasanthi Avadhanula; Laura L Ferlic-Stark; Kirtida D Patel; Felipe-Andres Piedra; Dimpy P Shah; Roy F Chemaly; Pedro A Piedra Journal: Vaccines (Basel) Date: 2020-04-21
Authors: Supriya Ravichandran; Elizabeth M Coyle; Laura Klenow; Juanjie Tang; Gabrielle Grubbs; Shufeng Liu; Tony Wang; Hana Golding; Surender Khurana Journal: Sci Transl Med Date: 2020-06-08 Impact factor: 17.956